Comparison of various radioactive payloads for a human monoclonal antibody to glycoprotein 41 for elimination of HIV-infected cells

Ravendra Garg, Kienna Mills, Kevin J.H. Allen, Patrick Causey, Randy W. Perron, Denise Gendron, Stephen Sanche, Joan W. Berman, Miroslaw K. Gorny, Ekaterina Dadachova

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Background: cART has significantly improved the life expectancy of people living with HIV (PLWH). However, it fails to eliminate the long-lived reservoir of latent HIV-infected cells. Radioimmunotherapy (RIT) relies on antigen-specific monoclonal antibodies (mAbs) for targeted delivery of lethal doses of ionizing radiation to cells. Previously, we have demonstrated that human mAb 2556 against HIV gp41 conjugated with 213Bismuth radioisotope (t1/2 = 46 min, alpha-emitter) selectively killed HIV-infected cells. 225Actinium (t1/2 = 9.92 d, alpha-emitter) and 177Lutetium (t1/2 = 6.7 d, beta-emitter) are two long-lived clinically proven radioisotopes for cancer treatment which might be more effective in killing infected cells systemically and in CNS. Methods: In this study we have conjugated 2556 mAb with 213Bi, 225Ac and 177Lu, and compared their ability to kill HIV-infected human peripheral blood mononuclear cells (PBMCs) and monocytes. PBMCs and monocytes from healthy donors were infected with HIVp49.5 and treated in vitro with increasing concentrations of 213Bi (4–20 μCi)-, 225Ac (20–100 nCi)- and 177Lu (4–50 μCi)-2556 mAb. Results: After three days post-treatment of infected PBMCs and monocytes, 213Bi- and 177Lu-conjugated 2556 mAb reduced virus production measured by p24 level in a dose-dependent manner, whereas, 225Ac-2556 showed minimal effect. However, seven days post-treatment all three radioisotopes showed significantly more pronounced reduction of virus replication as compared to control labeled mAb with 225Ac-2556 showing the least non-specific killing. Conclusion: These results indicate that RIT holds promise as a novel treatment option for the eradication of HIV-infected cells that merits further study in combination with cART and reactivation drugs.

Original languageEnglish (US)
Pages (from-to)80-88
Number of pages9
JournalNuclear Medicine and Biology
StatePublished - Mar 1 2020


  • 177-Lutetium
  • 213-Bismuth
  • 225-Actinium
  • Human monocytes
  • Human peripheral blood mononuclear cells
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging
  • Cancer Research


Dive into the research topics of 'Comparison of various radioactive payloads for a human monoclonal antibody to glycoprotein 41 for elimination of HIV-infected cells'. Together they form a unique fingerprint.

Cite this